# Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes

> **NCT04962906** · PHASE2 · COMPLETED · sponsor: **Ministerio de Salud de Ciudad Autónoma de Buenos Aires** · enrollment: 192 (actual)

## Conditions studied

- COVID-19 Vaccines

## Interventions

- **DRUG:** Gam-COVID-Vac / Gam-COVID-Vac

## Key facts

- **NCT ID:** NCT04962906
- **Lead sponsor:** Ministerio de Salud de Ciudad Autónoma de Buenos Aires
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-05
- **Primary completion:** 2021-08-05
- **Final completion:** 2021-08-15
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04962906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04962906, "Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04962906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*